Abstract:ABSTRACT Rotavirus causes severe diarrhea in infants. Although live attenuated rotavirus vaccines are available, vaccine-derived infections have been reported, which warrants development of next-generation rotavirus vaccines. A single-round infectious virus is a promising vaccine platform; however, this platform has not been studied extensively in the context of rotavirus. Here, we aimed to develop a single-round infectious rotavirus by impairing the function of the viral intermediate capsid protein VP6. Recombinant rotaviruses harboring mutations in VP6 were rescued using a reverse genetics system. Mutations were targeted at VP6 residues involved in virion assembly. Although the VP6-mutated rotavirus expressed viral proteins, it did not produce progeny virions in wild-type cells; however, the virus did produce progeny virions in VP6-expressing cells. This indicates that the VP6-mutated rotavirus is a single-round infectious rotavirus. Insertion of a foreign gene, and replacement of the VP7 gene segment with that of human rotavirus clinical isolates, was successful. No infectious virions were detected in mice infected with the single-round infectious rotavirus. Immunizing mice with the single-round infectious rotavirus induced neutralizing antibody titers as high as those induced by wild-type rotavirus. Taken together, the data suggest that this single-round infectious rotavirus has potential as a safe and effective rotavirus vaccine. This system is also applicable for generation of safe and orally administrable viral vectors. IMPORTANCE Rotavirus, a leading cause of acute gastroenteritis in infants, causes an annual estimated 128,500 infant deaths worldwide. Although live attenuated rotavirus vaccines are available, they are replicable and may cause vaccine-derived infections. Thus, development of safe and effective rotavirus vaccine is important. In this study, we report the development of a single-round infectious rotavirus that can replicate only in cells expressing viral VP6 protein. We demonstrated that (1) the single-round infectious rotavirus did not replicate in wild-type cells or in mice; (2) insertion of foreign genes and replacement of the outer capsid gene were possible; and (3) it was as immunogenic as the wild-type virus. Thus, the mutated virus shows promise as a next-generation rotavirus vaccine. The system is also applicable to orally administrable viral vectors, facilitating development of vaccines against other enteric pathogens.

Improved Characteristics and Protective Efficacy in an Animal Model of E. Coli-Derived Recombinant Double-Layered Rotavirus Virus-Like Particles

Characterization and Protective Efficacy in an Animal Model of a Novel Truncated Rotavirus VP8 Subunit Parenteral Vaccine Candidate.

Construction and characterization of human rotavirus recombinant VP8* subunit parenteral vaccine candidates.

Polymerization and Evaluation of the Protective Efficacy of Rotavirus VP4* Proteins

Rotavirus VP6 protein mucosally delivered by cell wall-derived particles from Lactococcus lactis induces protection against infection in a murine model

Self-assembling Rotavirus VP6 Nanoparticle Vaccines Expressed in Escherichia Coli Elicit Systemic and Mucosal Responses in Mice.

Safety, Immunogenicity, and Mechanism of a Rotavirus mRNA-LNP Vaccine in Mice

Lactobacillus acidophilus Expressing Murine Rotavirus VP8 and Mucosal Adjuvants Induce Virus-Specific Immune Responses

Virus-like Particles vaccine based on co-expression of G5 Porcine rotavirus VP2-VP6-VP7 induces a powerful immune protective response in mice

Immunogenicity and protective efficacy of rotavirus VP8* fused to cholera toxin B subunit in a mouse model

Inclusion of a Universal Tetanus Toxoid CD4+ T Cell Epitope P2 Significantly Enhanced the Immunogenicity of Recombinant Rotavirus ΔVP8* Subunit Parenteral Vaccines

Tandem Truncated Rotavirus VP8* Subunit Protein with T Cell Epitope As Non-Replicating Parenteral Vaccine is Highly Immunogenic

Generation of single-round infectious rotavirus with a mutation in the intermediate capsid protein VP6

A Milk-Based Self-Assemble Rotavirus VP6–ferritin Nanoparticle Vaccine Elicited Protection Against the Viral Infection

Genetic Engineering Subunit Vaccine of Group A Bovine Rotavirus

Bivalent rotavirus VP4∗ stimulates protective antibodies against common genotypes of human rotaviruses

Establishment of a Reverse Genetics System for Rotavirus Vaccine Strain LLR and Developing Vaccine Candidates Carrying VP7 Gene Cloned From Human Strains Circulating in China

The performance of licensed rotavirus vaccines and the development of a new generation of rotavirus vaccines: a review

Molecular Design of Encapsulin Protein Nanoparticles to Display Rotavirus Antigens for Enhancing Immunogenicity

The distinct impact of maternal antibodies on the immunogenicity of live and recombinant rotavirus vaccines

[Expression of the Main Structural Antigen VP6 of Human Rotavirus by Recombinant Adenovirus and Immune Responses Induced in Vivo].